Regarding the AD biomarkers, there were no differences in CSF tau or p‐tau levels, but CSF Aβ42 levels were significantly lower (t(20) = 3.98; P < 0.01) in the APOE ɛ4 carrier group (Table 1). Here, MAPT is linked to Alzheimer disease.